BRPI0615691A8 - Método para a preparação de 6-((3s,4r)-4-(4-amino-5-cloro-2-metoxibenzamido)-3-metoxipiperidin-1-il) hexanoato de (r)-quinuclidin-3-ila ou sal do mesmo - Google Patents

Método para a preparação de 6-((3s,4r)-4-(4-amino-5-cloro-2-metoxibenzamido)-3-metoxipiperidin-1-il) hexanoato de (r)-quinuclidin-3-ila ou sal do mesmo

Info

Publication number
BRPI0615691A8
BRPI0615691A8 BRPI0615691A BRPI0615691A BRPI0615691A8 BR PI0615691 A8 BRPI0615691 A8 BR PI0615691A8 BR PI0615691 A BRPI0615691 A BR PI0615691A BR PI0615691 A BRPI0615691 A BR PI0615691A BR PI0615691 A8 BRPI0615691 A8 BR PI0615691A8
Authority
BR
Brazil
Prior art keywords
hexanate
quinuclidin
methoxypiperidin
ila
chloro
Prior art date
Application number
BRPI0615691A
Other languages
English (en)
Inventor
By Kolbot
B Yeh J
Pang Ponny
Original Assignee
Aryx Therapeutics Inc
Armetheon Inc
Naronapride Llc
Renexxion Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aryx Therapeutics Inc, Armetheon Inc, Naronapride Llc, Renexxion Llc filed Critical Aryx Therapeutics Inc
Publication of BRPI0615691A2 publication Critical patent/BRPI0615691A2/pt
Publication of BRPI0615691A8 publication Critical patent/BRPI0615691A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

MÉTODO PARA A PREPARAÇÃO DE 6-((3S,4R)-4-(4-AMINO-5-CLORO-2-ETOXIBENZAMIDO)-3-METOXIPIPERIDIN-1-IL) HEXANOATO DE (R)-QUINUCLIDIN-3-ILA OU SAL DO MESMO. A presente invenção refere-se a métodos e/ou processos para síntese de compostos estereoisoméricos de fórmula (X): em que as variáveis são definidas neste documento e as composições para o tratamento seguro e eficiente de várias doenças gastrointestinais incluindo, a título de exemplo, gastroparesia, refluxo gastroesofágico e condições afins. Os compostos da presente invenção são também úteis no tratamento de vários distúrbios envolvendo o sistema nervoso central
BRPI0615691A 2005-08-31 2006-08-31 Método para a preparação de 6-((3s,4r)-4-(4-amino-5-cloro-2-metoxibenzamido)-3-metoxipiperidin-1-il) hexanoato de (r)-quinuclidin-3-ila ou sal do mesmo BRPI0615691A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US71314905P 2005-08-31 2005-08-31
US60/713,149 2005-08-31
US74776206P 2006-05-19 2006-05-19
US60/747,762 2006-05-19
PCT/US2006/034322 WO2007028073A2 (en) 2005-08-31 2006-08-31 Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders

Publications (2)

Publication Number Publication Date
BRPI0615691A2 BRPI0615691A2 (pt) 2011-05-24
BRPI0615691A8 true BRPI0615691A8 (pt) 2017-08-15

Family

ID=37708472

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0615691A BRPI0615691A8 (pt) 2005-08-31 2006-08-31 Método para a preparação de 6-((3s,4r)-4-(4-amino-5-cloro-2-metoxibenzamido)-3-metoxipiperidin-1-il) hexanoato de (r)-quinuclidin-3-ila ou sal do mesmo

Country Status (14)

Country Link
US (3) US7326787B2 (pt)
EP (1) EP1919909B1 (pt)
JP (1) JP5308818B2 (pt)
KR (1) KR101351454B1 (pt)
CN (1) CN102863374A (pt)
AU (1) AU2006284601B2 (pt)
BR (1) BRPI0615691A8 (pt)
CA (1) CA2620379C (pt)
DK (1) DK1919909T3 (pt)
ES (1) ES2436100T3 (pt)
IL (1) IL189202A (pt)
NO (1) NO340832B1 (pt)
RU (1) RU2418798C2 (pt)
WO (1) WO2007028073A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
EP1919909B1 (en) * 2005-08-31 2013-08-21 Armetheon, Inc. Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
WO2007149929A1 (en) * 2006-06-23 2007-12-27 Aryx Therapeutics, Inc. Piperidine derivatives for the treatment of gastrointestinal and cns disorders
IT1396373B1 (it) * 2009-10-29 2012-11-19 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina.
US10864367B2 (en) 2015-02-24 2020-12-15 Elira, Inc. Methods for using an electrical dermal patch in a manner that reduces adverse patient reactions
US10376145B2 (en) 2015-02-24 2019-08-13 Elira, Inc. Systems and methods for enabling a patient to achieve a weight loss objective using an electrical dermal patch
US10335302B2 (en) 2015-02-24 2019-07-02 Elira, Inc. Systems and methods for using transcutaneous electrical stimulation to enable dietary interventions
US10765863B2 (en) 2015-02-24 2020-09-08 Elira, Inc. Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy
US20220062621A1 (en) 2015-02-24 2022-03-03 Elira, Inc. Electrical Stimulation-Based Weight Management System
US9956393B2 (en) 2015-02-24 2018-05-01 Elira, Inc. Systems for increasing a delay in the gastric emptying time for a patient using a transcutaneous electro-dermal patch
US10143840B2 (en) 2015-02-24 2018-12-04 Elira, Inc. Systems and methods for enabling appetite modulation and/or improving dietary compliance using an electro-dermal patch
WO2020096911A1 (en) * 2018-11-05 2020-05-14 Renexxion, Llc Methods of producing naronapride trihydrate
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
GB1425706A (en) 1972-06-30 1976-02-18 Wyeth John & Brother Ltd Piperidine derivatives
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5137896A (en) * 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA1183847A (en) 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
SU1593569A3 (ru) * 1982-07-30 1990-09-15 Janssen Pharmaceutica Nv Cпocoб пoлучehия пpoизboдhыx n-(3-гидpokcи-4-пипepидиhил)бehзamидa или иx kиcлotho-aддиtиbhыx coлeй
CZ284687B6 (cs) * 1986-04-30 1999-02-17 Dainippon Pharmaceutical Co., Ltd. Substituovaný benzamidový derivát, způsob jeho výroby a farmaceutický prostředek na jeho bázi
US4875439A (en) * 1987-01-09 1989-10-24 Brunswick Corporation Marine propulsion system with fuel line cooler
CA1317940C (en) 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US5041454A (en) * 1987-09-25 1991-08-20 Janssen Pharmaceutica N.V. Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US4975439A (en) * 1987-09-25 1990-12-04 Janssen Pharmaceutical N.V. Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
GB8902118D0 (en) * 1989-02-01 1989-03-22 Beecham Group Plc Chemical process
TW243449B (pt) * 1991-02-15 1995-03-21 Hokuriku Pharmaceutical
US5395832A (en) * 1991-02-15 1995-03-07 Hokuriku Seiyaku Co., Ltd. Benzamide derivatives
JPH07501063A (ja) * 1991-11-14 1995-02-02 グラクソ、グループ、リミテッド フィブリノーゲン依存性血小板凝集阻害剤としてのピペリジン酢酸誘導体
IT1260485B (it) * 1992-05-29 1996-04-09 Procedimento e dispositivo per il trattamento dell'obesita' di un paziente
EP1145715A3 (en) * 1992-07-07 2004-05-19 Sepracor Inc. Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
EP0651639A4 (en) * 1992-07-07 1996-06-26 Sepracor Inc METHODS OF USING CISAPRIDE (+) FOR THE TREATMENT OF GASTROSOPHAGIC REFLUX AND OTHER DISORDERS.
US5705498A (en) * 1992-11-05 1998-01-06 Smithkline Beecham Plc. Piperidine derivatives as 5-HT4 receptor antagonists
US5472866A (en) * 1992-12-24 1995-12-05 Synaptic Pharmaceutical Corporation DNA encoding 5-HT4A serotonin receptors
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
US6147093A (en) * 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
HUP0003078A3 (en) 1997-07-11 2002-02-28 Janssen Pharmaceutica Nv (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders
JPH11292846A (ja) 1998-02-10 1999-10-26 Hokuriku Seiyaku Co Ltd ベンズアミド誘導体及びそれを含有する医薬
AR022338A1 (es) 1999-02-04 2002-09-04 Hokuriku Pharmaceutical Un compuesto de benzamida, medicamento que lo contiene, y uso para la manufactura de un medicamento para el tratamiento o prevencion de una enfermedad digestiva o para mejorar la movilidad del tracto gastrointestinal.
DE19933926A1 (de) 1999-07-20 2001-01-25 Boehringer Ingelheim Pharma Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
US6552046B2 (en) * 2000-06-07 2003-04-22 Aryx Therapeutics Materials and methods for the treatment of gastroesophageal reflux disease
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
CA2551686C (en) * 2004-01-07 2014-09-23 Ian Irwin Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
EP1919909B1 (en) 2005-08-31 2013-08-21 Armetheon, Inc. Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders

Also Published As

Publication number Publication date
US20090137810A1 (en) 2009-05-28
JP5308818B2 (ja) 2013-10-09
CA2620379C (en) 2015-02-24
WO2007028073A2 (en) 2007-03-08
WO2007028073A3 (en) 2007-05-24
US20080076927A1 (en) 2008-03-27
US20070078265A1 (en) 2007-04-05
KR20080041294A (ko) 2008-05-09
EP1919909A2 (en) 2008-05-14
KR101351454B1 (ko) 2014-01-14
IL189202A (en) 2013-07-31
AU2006284601B2 (en) 2012-12-20
BRPI0615691A2 (pt) 2011-05-24
CA2620379A1 (en) 2007-03-08
EP1919909B1 (en) 2013-08-21
AU2006284601A1 (en) 2007-03-08
HK1121762A1 (en) 2009-04-30
ES2436100T3 (es) 2013-12-27
IL189202A0 (en) 2008-06-05
US7326787B2 (en) 2008-02-05
RU2008112215A (ru) 2009-10-10
CN102863374A (zh) 2013-01-09
NO20081562L (no) 2008-03-28
NO340832B1 (no) 2017-06-26
DK1919909T3 (da) 2013-12-02
RU2418798C2 (ru) 2011-05-20
US7629466B2 (en) 2009-12-08
JP2009507033A (ja) 2009-02-19

Similar Documents

Publication Publication Date Title
BRPI0506736A (pt) composto estereoisoméricos e métodos para o tratamento de distúrbios gastrointestinais e no sistema nervoso central
BRPI0417543A (pt) quinolinas úteis no tratamento de doença cardiovascular
EA201100299A1 (ru) Органические соединения
EA201100094A1 (ru) Тиадиазолилоксифениламидины и их применение в качестве фунгицидов
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
WO2006113919A3 (en) Aryl alkyl acid derivatives for and use thereof
CO6382126A2 (es) Compuestos heteroaromaticos fusionados y espirociclicos para el tratamiento de infecciones bacterianas
BRPI0507034A (pt) compostos orgánicos
BRPI0712101B8 (pt) ácido beta-fenil-alfa-hidróxi propanóico substituído, método de síntese e uso do mesmo
BRPI0413245A (pt) compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
BRPI0410238A (pt) compostos orgánicos
NO20081562L (no) Syntetiske metoder og mellomprodukt for stereoisomeriske forbindelser som er nyttige for behandlingen av gastrointestinale og sentralnervesystemersykdommer
WO2007068894A3 (en) Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
MX2009003981A (es) Agentes moduladores del receptor de calcio.
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
WO2007052023A3 (en) Novel compounds
BRPI0411738A (pt) compostos orgánicos
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
BR0308419A (pt) Derivados de azetidina como antagonistas do receptor ccr-3
WO2009009122A3 (en) Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
MX2009005351A (es) Compuestos utiles para tratar trastornos neurodegenerativos.
WO2007013936A3 (en) Method for treating nervous system disorders and conditions
ATE440836T1 (de) Verbindungen

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ARMETHEON, INC (US)

B25A Requested transfer of rights approved

Owner name: NARONAPRIDE LLC (US)

B25D Requested change of name of applicant approved

Owner name: RENEXXION LLC (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]